Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
In a regulatory filing, the pharma major said, ?Granules India announced that the US Food & Drug Administration (US FDA) has approved its abbreviated new drug application (ANDA), filed by Granules Pharmaceuticals, Inc, a wholly owned foreign subsidiary of the company, for Sildenafil for Oral Suspension.?
Sildenafil for oral suspension is indicated for the treatment of pulmonary arterial hypertension (world health organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.
The current annual U.S. market for Sildenafil for oral suspension is approximately $43 million, according to MAT September 2023, IQVIA/IMS Health.
Granules now have a total of 63 ANDA approvals from the US FDA (61 final approvals and 2 tentative approvals).
Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).
The company?s consolidated net profit declined 29.6% to Rs 102.12 crore despite of 3.4% rise in net sales to Rs 1,189.49 crore in Q2 FY24 over Q2 FY23.
Shares of Granules India added 0.13% to Rs 393.20 on the BSE.
Powered by Capital Market - Live News